← Back to Clinical Trials
Recruiting NCT03457831

NCT03457831 Status Epilepticus in the Critically Ill Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03457831
Status Recruiting
Phase
Sponsor Ictal Group
Condition Status Epilepticus
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2018-02-28
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2018-02-28 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Convulsive and Non Convulsive Status Epilepticus (SE) and Pseudo Status Epilepticus prospective registry. Data collection using a standardized form : demographic data and data related to the SE, including circumstances of onset, dates and times of onset and of seizure control, on-scene clinical findings, clinical features of the seizures, pre-hospital and hospital care providers, timing of antiepileptic and supportive treatments, results of etiological investigations, cause of SE, type and dosage of antiepileptic drugs. Dates and times of EEG monitoring, EEG results. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview.

Eligibility Criteria

Inclusion Criteria: * SE defined as 5 min or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures. * age \>= 18 years Exclusion Criteria: * age \< 18 years * postanoxic status epilepticus

Contact & Investigator

Central Contact

stephane LEGRIEL, MD

✉ slegriel@ch-versailles.fr

📞 +33139639717

Principal Investigator

stephane LEGRIEL, MD

PRINCIPAL INVESTIGATOR

Ictal Group

Frequently Asked Questions

Who can join the NCT03457831 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Status Epilepticus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03457831 currently recruiting?

Yes, NCT03457831 is actively recruiting participants. Contact the research team at slegriel@ch-versailles.fr for enrollment information.

Where is the NCT03457831 trial being conducted?

This trial is being conducted at Angoulême, France, Beauvais, France, Beuvry, France, Brest, France and 11 additional locations.

Who is sponsoring the NCT03457831 clinical trial?

NCT03457831 is sponsored by Ictal Group. The principal investigator is stephane LEGRIEL, MD at Ictal Group. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology